Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function
Context: Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed. Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia....
Gespeichert in:
Veröffentlicht in: | The journal of clinical endocrinology and metabolism 2016-11, Vol.101 (11), p.4076-4084 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4084 |
---|---|
container_issue | 11 |
container_start_page | 4076 |
container_title | The journal of clinical endocrinology and metabolism |
container_volume | 101 |
creator | Patel, Y. R Kirkman, M. S Considine, R. V Hannon, T. S Mather, K. J |
description | Context:
Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed.
Objective:
To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia.
Design:
EDIP was a randomized, placebo-controlled trial.
Setting:
Two university diabetes centers.
Patients:
A total of 219 overweight individuals with fasting glucose < 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose > 11.1 mmol/L.
Interventions:
Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years.
Main Outcome Measures:
Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression.
Results:
Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes.
Conclusions:
In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes.
Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes. |
doi_str_mv | 10.1210/jc.2016-2056 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5095260</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1835428262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4734-93c4b86f037af2bc88e00355ae4f7258256b5c4b426748d576bb8cf2e18774163</originalsourceid><addsrcrecordid>eNptkctu1TAQhiMEoofCjjXykgUpvsbJBqkKbTlSJViAYGc5PpPLIbGD7bTqinfqg_SZcDilAglL9mjkb_4Z-8-ylwSfEErw2705oZgUOcWieJRtSMVFLkklH2cbjCnJK0m_HWXPQthjTDgX7Gl2RKVgjGG5yX7WvbYdBDRY9BWGro9I2x26GBfjAqBaW_TJuwgmotNODzbENe88hDA4u1adaT_eoPeDbiAmna3dwQzpsBG5Fm2n2bsrmFL6u8fdbV7DOKLzxZqYFJ5nT1o9BnhxH4-zL-dnn-sP-eXHi219epkbLhnPK2Z4UxYtZlK3tDFlCRgzITTwVlJRUlE0IiGcFpKXOyGLpilNS4GUUnJSsOPs3UF3XpoJdibN4_WoZj9M2t8opwf1740detW5KyVwJWiBk8DrewHvfiwQopqGYNJTtAW3BEVKJjgtaUET-uaAGu9C8NA-tCFYrZ6pvVGrZ2r1LOGv_h7tAf5jUgL4Abh2YwQfvo_LNXjVgx5jr3BavJBlvioSkrI8bcpTGTuUJTec8YOFebVN7d3ibfrr_0_zCzaJtJY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1835428262</pqid></control><display><type>article</type><title>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Patel, Y. R ; Kirkman, M. S ; Considine, R. V ; Hannon, T. S ; Mather, K. J</creator><creatorcontrib>Patel, Y. R ; Kirkman, M. S ; Considine, R. V ; Hannon, T. S ; Mather, K. J</creatorcontrib><description>Context:
Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed.
Objective:
To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia.
Design:
EDIP was a randomized, placebo-controlled trial.
Setting:
Two university diabetes centers.
Patients:
A total of 219 overweight individuals with fasting glucose < 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose > 11.1 mmol/L.
Interventions:
Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years.
Main Outcome Measures:
Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression.
Results:
Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes.
Conclusions:
In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes.
Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.</description><identifier>ISSN: 0021-972X</identifier><identifier>EISSN: 1945-7197</identifier><identifier>DOI: 10.1210/jc.2016-2056</identifier><identifier>PMID: 27533307</identifier><language>eng</language><publisher>United States: Endocrine Society</publisher><subject>Acarbose - administration & dosage ; Acarbose - pharmacology ; Adult ; Aged ; Blood Glucose - metabolism ; Combined Modality Therapy ; Diabetes Mellitus, Type 2 - blood ; Diabetes Mellitus, Type 2 - therapy ; Diet, Carbohydrate-Restricted - methods ; Diet, Reducing - methods ; Disease Progression ; Female ; Glycoside Hydrolase Inhibitors - administration & dosage ; Glycoside Hydrolase Inhibitors - pharmacology ; Humans ; Insulin-Secreting Cells - metabolism ; Male ; Middle Aged ; Original ; Outcome Assessment (Health Care) ; Overweight - blood ; Overweight - therapy ; Weight Loss</subject><ispartof>The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.4076-4084</ispartof><rights>Copyright © 2016 by the Endocrine Society</rights><rights>Copyright © 2016 by The Endocrine Society</rights><rights>Copyright © 2016 by the Endocrine Society 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4734-93c4b86f037af2bc88e00355ae4f7258256b5c4b426748d576bb8cf2e18774163</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27533307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patel, Y. R</creatorcontrib><creatorcontrib>Kirkman, M. S</creatorcontrib><creatorcontrib>Considine, R. V</creatorcontrib><creatorcontrib>Hannon, T. S</creatorcontrib><creatorcontrib>Mather, K. J</creatorcontrib><title>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</title><title>The journal of clinical endocrinology and metabolism</title><addtitle>J Clin Endocrinol Metab</addtitle><description>Context:
Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed.
Objective:
To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia.
Design:
EDIP was a randomized, placebo-controlled trial.
Setting:
Two university diabetes centers.
Patients:
A total of 219 overweight individuals with fasting glucose < 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose > 11.1 mmol/L.
Interventions:
Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years.
Main Outcome Measures:
Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression.
Results:
Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes.
Conclusions:
In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes.
Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.</description><subject>Acarbose - administration & dosage</subject><subject>Acarbose - pharmacology</subject><subject>Adult</subject><subject>Aged</subject><subject>Blood Glucose - metabolism</subject><subject>Combined Modality Therapy</subject><subject>Diabetes Mellitus, Type 2 - blood</subject><subject>Diabetes Mellitus, Type 2 - therapy</subject><subject>Diet, Carbohydrate-Restricted - methods</subject><subject>Diet, Reducing - methods</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Glycoside Hydrolase Inhibitors - administration & dosage</subject><subject>Glycoside Hydrolase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Insulin-Secreting Cells - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Original</subject><subject>Outcome Assessment (Health Care)</subject><subject>Overweight - blood</subject><subject>Overweight - therapy</subject><subject>Weight Loss</subject><issn>0021-972X</issn><issn>1945-7197</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkctu1TAQhiMEoofCjjXykgUpvsbJBqkKbTlSJViAYGc5PpPLIbGD7bTqinfqg_SZcDilAglL9mjkb_4Z-8-ylwSfEErw2705oZgUOcWieJRtSMVFLkklH2cbjCnJK0m_HWXPQthjTDgX7Gl2RKVgjGG5yX7WvbYdBDRY9BWGro9I2x26GBfjAqBaW_TJuwgmotNODzbENe88hDA4u1adaT_eoPeDbiAmna3dwQzpsBG5Fm2n2bsrmFL6u8fdbV7DOKLzxZqYFJ5nT1o9BnhxH4-zL-dnn-sP-eXHi219epkbLhnPK2Z4UxYtZlK3tDFlCRgzITTwVlJRUlE0IiGcFpKXOyGLpilNS4GUUnJSsOPs3UF3XpoJdibN4_WoZj9M2t8opwf1740detW5KyVwJWiBk8DrewHvfiwQopqGYNJTtAW3BEVKJjgtaUET-uaAGu9C8NA-tCFYrZ6pvVGrZ2r1LOGv_h7tAf5jUgL4Abh2YwQfvo_LNXjVgx5jr3BavJBlvioSkrI8bcpTGTuUJTec8YOFebVN7d3ibfrr_0_zCzaJtJY</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Patel, Y. R</creator><creator>Kirkman, M. S</creator><creator>Considine, R. V</creator><creator>Hannon, T. S</creator><creator>Mather, K. J</creator><general>Endocrine Society</general><general>Copyright by The Endocrine Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201611</creationdate><title>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</title><author>Patel, Y. R ; Kirkman, M. S ; Considine, R. V ; Hannon, T. S ; Mather, K. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4734-93c4b86f037af2bc88e00355ae4f7258256b5c4b426748d576bb8cf2e18774163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acarbose - administration & dosage</topic><topic>Acarbose - pharmacology</topic><topic>Adult</topic><topic>Aged</topic><topic>Blood Glucose - metabolism</topic><topic>Combined Modality Therapy</topic><topic>Diabetes Mellitus, Type 2 - blood</topic><topic>Diabetes Mellitus, Type 2 - therapy</topic><topic>Diet, Carbohydrate-Restricted - methods</topic><topic>Diet, Reducing - methods</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Glycoside Hydrolase Inhibitors - administration & dosage</topic><topic>Glycoside Hydrolase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Insulin-Secreting Cells - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Original</topic><topic>Outcome Assessment (Health Care)</topic><topic>Overweight - blood</topic><topic>Overweight - therapy</topic><topic>Weight Loss</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patel, Y. R</creatorcontrib><creatorcontrib>Kirkman, M. S</creatorcontrib><creatorcontrib>Considine, R. V</creatorcontrib><creatorcontrib>Hannon, T. S</creatorcontrib><creatorcontrib>Mather, K. J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The journal of clinical endocrinology and metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patel, Y. R</au><au>Kirkman, M. S</au><au>Considine, R. V</au><au>Hannon, T. S</au><au>Mather, K. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function</atitle><jtitle>The journal of clinical endocrinology and metabolism</jtitle><addtitle>J Clin Endocrinol Metab</addtitle><date>2016-11</date><risdate>2016</risdate><volume>101</volume><issue>11</issue><spage>4076</spage><epage>4084</epage><pages>4076-4084</pages><issn>0021-972X</issn><eissn>1945-7197</eissn><abstract>Context:
Evidence-based strategies to prevent progression of dysglycemia in newly diagnosed type 2 diabetes are needed.
Objective:
To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in order to understand the features that were protective against worsening glycemia.
Design:
EDIP was a randomized, placebo-controlled trial.
Setting:
Two university diabetes centers.
Patients:
A total of 219 overweight individuals with fasting glucose < 7.8 mmol/L and 2-hour oral glucose tolerance test (OGTT) glucose > 11.1 mmol/L.
Interventions:
Acarbose versus placebo, on a background of dietary recommendations, with quarterly visits to assess glycemia and intervention adherence for up to 5 years.
Main Outcome Measures:
Progression of fasting glucose ≥ 7.8 mmol/L on two consecutive quarterly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate determinants of progression.
Results:
Progression-free status was associated with reductions in weight, fasting glucose, 2-hour OGTT glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glucose was the only effect that remained significantly associated with progression-free status in multivariable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reductions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes.
Conclusions:
In early diabetes, reductions in glucose, driven by reductions in weight, can delay progressive metabolic worsening. These observations underscore the importance of lifestyle management including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed diabetes.
Reductions in fasting glucose, via reductions in weight, provided protection from progressive dysglycemia in EDIP. Lifestyle change can contribute importantly to glycemic control in early diabetes.</abstract><cop>United States</cop><pub>Endocrine Society</pub><pmid>27533307</pmid><doi>10.1210/jc.2016-2056</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-972X |
ispartof | The journal of clinical endocrinology and metabolism, 2016-11, Vol.101 (11), p.4076-4084 |
issn | 0021-972X 1945-7197 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5095260 |
source | MEDLINE; Journals@Ovid Complete; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
subjects | Acarbose - administration & dosage Acarbose - pharmacology Adult Aged Blood Glucose - metabolism Combined Modality Therapy Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - therapy Diet, Carbohydrate-Restricted - methods Diet, Reducing - methods Disease Progression Female Glycoside Hydrolase Inhibitors - administration & dosage Glycoside Hydrolase Inhibitors - pharmacology Humans Insulin-Secreting Cells - metabolism Male Middle Aged Original Outcome Assessment (Health Care) Overweight - blood Overweight - therapy Weight Loss |
title | Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T09%3A33%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changes%20in%20Weight%20and%20Glucose%20Can%20Protect%20Against%20Progression%20in%20Early%20Diabetes%20Independent%20of%20Improvements%20in%20%CE%B2-Cell%20Function&rft.jtitle=The%20journal%20of%20clinical%20endocrinology%20and%20metabolism&rft.au=Patel,%20Y.%20R&rft.date=2016-11&rft.volume=101&rft.issue=11&rft.spage=4076&rft.epage=4084&rft.pages=4076-4084&rft.issn=0021-972X&rft.eissn=1945-7197&rft_id=info:doi/10.1210/jc.2016-2056&rft_dat=%3Cproquest_pubme%3E1835428262%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1835428262&rft_id=info:pmid/27533307&rfr_iscdi=true |